# MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer

> **NCT01628471** · PHASE1,PHASE2 · COMPLETED · sponsor: **Uman Pharma** · enrollment: 20 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** decitabine in combination with genistein

## Key facts

- **NCT ID:** NCT01628471
- **Lead sponsor:** Uman Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2015-05
- **Final completion:** 2015-09
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2015-09-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01628471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01628471, "MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01628471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*